Novogene Bioinformatics Institute BeijingChina

Novogene Bioinformatics Institute BeijingChina

SEARCH FILTERS
Time filter
Source Type

Gao J.,Peking University | Wang H.,Peking University | Zang W.,Novogene Bioinformatics Institute BeijingChina | Li B.,Peking University | And 8 more authors.
Cancer Science | Year: 2017

Overcoming tumor heterogeneity is a major challenge for personalized treatment of gastric cancer, especially for human epidermal growth factor receptor-2 targeted therapy. Analysis of circulating tumor DNA allows a more comprehensive analysis of tumor heterogeneity than traditional biopsies in lung cancer and breast cancer, but little is known in gastric cancer. We assessed mutation profiles of ctDNA and primary tumors from 30 patients with advanced gastric cancer, then performed a comprehensive analysis of tumor mutations by multiple biopsies from five patients, and finally analyzed the concordance of HER2 amplification in ctDNA and paired tumor tissues in 70 patients. By comparing with a single tumor sample, ctDNA displayed a low concordance of mutation profile, only approximately 50% (138/275) somatic mutations were found in paired tissue samples, however, when compared with multiple biopsies, most DNA mutations in ctDNA were also shown in paired tumor tissues. ctDNA had a high concordance (91.4%, Kappa index = 0.784, P < 0.001) of HER2 amplification with tumor tissues, suggesting it might be an alternative for tissue. It implied that ctDNA-based assessment could partially overcome the tumor heterogeneity, and might serve as a potential surrogate for HER2 analysis in gastric cancer. © 2017 Japanese Cancer Association.

Loading Novogene Bioinformatics Institute BeijingChina collaborators
Loading Novogene Bioinformatics Institute BeijingChina collaborators